A Phase III Prospective Double Blind Placebo Controlled Randomized Study on the effect of Adjuvant MEDI4736 on Disease Free Survival In patients with Completely Resected Non-Small Cell Lung Cancer

Trial Profile

A Phase III Prospective Double Blind Placebo Controlled Randomized Study on the effect of Adjuvant MEDI4736 on Disease Free Survival In patients with Completely Resected Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BR.31
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Apr 2015 New source identified and integrated as Australian New Zealand Clinical Trials Registry (ACTRN12615000323527)
    • 12 Oct 2014 Status changed from not yet recruiting to recruiting as reported by National Cancer Institute of Canada record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top